Get the Stockscreener App
1.91
2.69%
0.05
After Hours:
1.89
-0.02
-1.05%
Armata Pharmaceuticals Inc stock is traded at $1.91, with a volume of 7,287.
It is up +2.69% in the last 24 hours and up +41.48% over the past month.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections in the United States. The company develops its products using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company is also developing and advancing synthetic phage for treating diseases caused by pseudomonas aeruginosa. Armata Pharmaceuticals, Inc. is headquartered in Marina del Rey, California.
See More
Previous Close:
$1.86
Open:
$1.75
24h Volume:
7,287
Relative Volume:
0.03
Market Cap:
$73.83M
Revenue:
-
Net Income/Loss:
$-41.36M
P/E Ratio:
-1.1646
EPS:
-1.64
Net Cash Flow:
$-42.09M
1W Performance:
-5.91%
1M Performance:
+41.48%
6M Performance:
-2.05%
1Y Performance:
-31.05%
1-Day Range:
$1.75
$1.9698
1-Week Range:
$1.74
$2.1191
52-Week Range:
$0.8981
$3.4154
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Name
Armata Pharmaceuticals Inc
Sector
Industry
Phone
310-655-2928
Address
4503 Glencoe Avenue, Marina del Rey, CA
Compare ARMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
1.91 | 73.83M | 0 | -41.36M | -42.09M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-19-19 | Initiated | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Stock (ARMP) Latest News
Armata Pharmaceuticals Elects Board Members at Annual Meeting - TipRanks
Chronic Pseudomonas aeruginosa Pulmonary Infections Pipeline - openPR.com
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - Seeking Alpha
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Declines By 44.0% - Defense World
10 Best Healthcare Stocks to Invest In (June 2025) - Securities.io
ARMP Soars 72% in a Month Following Infectious Disease Study Success - MSN
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Biotech Alert: Searches spiking for these stocks today - TipRanks
Armata Pharmaceuticals (ARMP) Experiences Massive Surge in Inter - GuruFocus
Armata Pharmaceuticals Q4 EPS Reduced by HC Wainwright - Defense World
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Price Target Raised to $9.00 at HC Wainwright - Defense World
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia | ARMP Stock News - GuruFocus
Armata Pharmaceuticals (ARMP) Receives Boosted Price Target from - GuruFocus
HC Wainwright Adjusts Armata Pharmaceuticals Price Target to $9 From $7, Maintains Buy Rating - marketscreener.com
Armata Pharmaceuticals (ARMP) Price Target Boosted Following Cli - GuruFocus
ARMP: Positive Results from Armata Pharmaceuticals' AP-SA02 Tria - GuruFocus
Armata reports data from Phase 1b/2a diSArm trial - TipRanks
Armata Pharmaceuticals Announces Positive Topline Data from the - GuruFocus
ARMP: Positive Results from Armata Pharmaceuticals' AP-SA02 Trial | ARMP Stock News - GuruFocus
Armata Pharmaceuticals Reports Positive Phase 1b/2a Trial Results - TipRanks
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia - PR Newswire
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates - MSN
Armata Pharmaceuticals Inc (ARMP) Q1 Earnings: EPS Loss of $0.18 - GuruFocus
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update | ARMP Stock News - GuruFocus
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update - Financial Times
New Strong Sell Stocks for May 8th - The Globe and Mail
Armata Pharmaceuticals (ARMP) to Release Earnings on Tuesday - Defense World
Armata Pharmaceuticals secures additional DoD funding - Investing.com
Armata Pharmaceuticals (ARMP) Secures Additional $4.65M for Clin - GuruFocus
Armata Pharmaceuticals Receives $4.65 Million of Additional Non- - GuruFocus
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 | ARMP Stock News - GuruFocus
Armata Pharmaceuticals secures additional DoD funding By Investing.com - Investing.com Nigeria
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - Yahoo Finance
New Strong Sell Stocks for April 28th - The Globe and Mail
New Strong Sell Stocks for April 24th - TradingView
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 28.3% - Defense World
Bacteriophage Therapy Market Future Business Opportunities - openPR
HC Wainwright Comments on Armata Pharmaceuticals Q1 Earnings - Defense World
Armata Pharmaceuticals Inc (ARMP) Q4 2024 Earnings: EPS of $0.07 - GuruFocus
Armata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last year - MSN
Armata Pharmaceuticals Inc. (ARMP) reports earnings - Quartz
Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update - MarketScreener
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PR Newswire
Armata Pharmaceuticals (ARMP) Projected to Post Quarterly Earnings on Thursday - The AM Reporter
Armata Pharmaceuticals secures $10 million credit By Investing.com - Investing.com Australia
Armata Pharmaceuticals secures $10 million credit - Investing.com India
Armata Pharmaceuticals Secures $10M Loan for Clinical Trials - TipRanks
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - Eastern Progress
Armata Pharmaceuticals Inc Stock (ARMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.13%
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):